534 related articles for article (PubMed ID: 16313266)
1. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
2. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F
Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
4. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
5. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
6. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
8. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
10. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
12. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
14. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
[TBL] [Abstract][Full Text] [Related]
15. Use of single-dose rasburicase in an obese female.
Arnold TM; Reuter JP; Delman BS; Shanholtz CB
Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
[TBL] [Abstract][Full Text] [Related]
16. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
17. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
18. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
20. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
